MSL
ICPT

Mackay Shields LLC’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Mackay Shields LLC’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-13,040
Closed -$301K – 1412
2021
Q1 		$301K Sell
13,040
-30,586
-70% -$853K ﹤0.01% 1327
2020
Q4 		$1.08M Sell
43,626
-2,100
-5% -$69.6K 0.01% 1069
2020
Q3 		$1.9M Buy
45,726
+16,200
+55% +$744K 0.01% 810
2020
Q2 		$1.42M Buy
29,526
+10,500
+55% +$811K 0.01% 903
2020
Q1 		$1.2M Sell
19,026
-1,400
-7% -$126K 0.01% 884
2019
Q4 		$2.53M Sell
20,426
-2,900
-12% -$260K 0.02% 775
2019
Q3 		$1.55M Buy
23,326
+1,200
+5% +$80.6K 0.01% 1007
2019
Q2 		$1.76M Buy
22,126
+14,365
+185% +$1.29M 0.01% 946
2019
Q1 		$868K Buy
7,761
+200
+3% +$21.9K 0.01% 1042
2018
Q4 		$762K Sell
7,561
-239
-3% -$24.8K 0.01% 1020
2018
Q3 		$986K Buy
+7,800
New +$825K 0.01% 878

Other funds holding ICPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Mackay Shields LLC's ICPT Position: Q2 2021 in Review

Mackay Shields LLC sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q2 2021, closing a stake of 13,040 shares — an estimated $301K sold.

Mackay Shields LLC first reported a position in ICPT in Q3 2018 and held it in 11 quarters. The position peaked at $2.53M in Q4 2019. 129 funds tracked by Wall St. Rank hold ICPT as of Q2 2021.

  • Mackay Shields LLC reported no remaining Intercept Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
  • Mackay Shields LLC sold 13,040 Intercept Pharmaceuticals, Inc. shares in Q2 2021, an estimated $301K.
  • Mackay Shields LLC first reported a position in Intercept Pharmaceuticals, Inc. in Q3 2018 and held it in 11 quarters.
  • Mackay Shields LLC's Intercept Pharmaceuticals, Inc. position peaked at $2.53M in Q4 2019.
  • 129 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2021.

Based on Mackay Shields LLC's 13F filing for Q2 2021, filed 13 Aug 2021.